These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12463470)

  • 1. Bisphosphonates--targeting bone in the treatment of spondyloarthritis.
    Haibel H; Braun J; Maksymowych WP
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S162-6. PubMed ID: 12463470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis.
    Toussirot E; Wendling D
    Curr Opin Rheumatol; 2007 Jul; 19(4):340-5. PubMed ID: 17551363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.
    Santra G; Sarkar RN; Phaujdar S; Banerjee S; Siddhanta S
    Singapore Med J; 2010 Nov; 51(11):883-7. PubMed ID: 21140116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.
    Mok CC; Li OC; Chan KL; Ho LY; Hui PK
    Scand J Rheumatol; 2015; 44(6):480-6. PubMed ID: 26271141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open study of pamidronate in the treatment of refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Leclercq S; Skeith K; Yan A; Russell AS
    J Rheumatol; 1998 Apr; 25(4):714-7. PubMed ID: 9558174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies.
    Toussirot E; Wendling D
    Expert Opin Pharmacother; 2005 Jan; 6(1):35-43. PubMed ID: 15709881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, new bone formation and treatment options in axial spondyloarthritis.
    Sieper J; Poddubnyy D
    Ann Rheum Dis; 2014 Aug; 73(8):1439-41. PubMed ID: 24812284
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?
    Wendling D
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):5-7. PubMed ID: 23216081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacotherapy of spondyloarthritis].
    Curković B
    Reumatizam; 2011; 58(2):65-8. PubMed ID: 22232952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs.
    Poddubnyy D; van der Heijde D
    Rheum Dis Clin North Am; 2012 Aug; 38(3):601-11. PubMed ID: 23083758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to optimize the antiTNF alpha therapy in spondylitis?].
    Castro Villegas Mdel C; Escudero Contreras A; Miranda García MD; Collantes Estévez E
    Reumatol Clin; 2012 Mar; 8 Suppl 1():S26-31. PubMed ID: 22418285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
    Adiyaman P; Ocal G; Berberoğlu M; Evliyaoğlu O; Aycan Z; Cetinkaya E
    Turk J Pediatr; 2004; 46(4):322-8. PubMed ID: 15641265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
    Yoon SH; Sugamori KS; Grynpas MD; Mitchell J
    Neuromuscul Disord; 2016 Jan; 26(1):73-84. PubMed ID: 26494410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.
    Bravenboer N; Papapoulos SE; Holzmann P; Hamdy NA; Netelenbos JC; Lips P
    Osteoporos Int; 1999; 9(6):489-93. PubMed ID: 10624455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects].
    Corrado A; Cantatore FP
    Reumatismo; 2005; 57(3):142-53. PubMed ID: 16258598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover.
    Cairns AP; Wright SA; Taggart AJ; Coward SM; Wright GD
    Ann Rheum Dis; 2005 Feb; 64(2):338-9. PubMed ID: 15096328
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of pamidronate on the development of changes in bone mechanical properties and bone structure caused by the administration of prednisolone in rats.
    Tkocz-Kwiatkowska J; Kaczmarczyk-Sedlak I; Folwarczna J
    Pol J Pharmacol; 1998; 50(3):253-8. PubMed ID: 9861633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamidronate treatment in SAPHO syndrome.
    Guignard S; Job-Deslandre C; Sayag-Boukris V; Kahan A
    Joint Bone Spine; 2002 Jun; 69(4):392-6. PubMed ID: 12184437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.